Yanjie Li1, Hujun Li2, Wenjing Li2, Lijin Wang2, Zhiling Yan2, Yao Yao3, Ruosi Yao3, Kailin Xu2, Zhenyu Li2. 1. Laboratory Center of Diagnostics, Xuzhou Medical University, Xuzhou, China. 2. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. 3. Institute of Haematology, Xuzhou Medical University, Xuzhou, China.
Abstract
BACKGROUND: We evaluated the prognostic significance of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patients with multiple myeloma (MM). METHODS: In total, we retrospectively analyzed 315 newly diagnosed MM patients and calculated NLR and PLR from the complete blood count of the untreated patients. We further assessed the role of pretreatment NLR and PLR on overall survival (OS) and progression-free survival (PFS). RESULTS: Multiple myeloma patients with high NLR (≥2) experienced shorter OS (P=.02) and PFS (P=.01) compared with patients with low NLR (<2). Furthermore, among the patients with conventional chemotherapy, elderly patients, or patients with advanced stages, high NLR (≥2) was found to have a negative prognostic impact on OS and PFS. In the multivariate Cox analysis, we confirmed that the NLR was an independent prognostic factor for both OS and PFS (P=.000). But the differences in OS or PFS by PLR were not found in MM patients. CONCLUSIONS: Our study suggests that NLR not PLR can be acted as an independent prognostic factor for analyzing the clinical outcome of MM patients.
BACKGROUND: We evaluated the prognostic significance of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patients with multiple myeloma (MM). METHODS: In total, we retrospectively analyzed 315 newly diagnosed MMpatients and calculated NLR and PLR from the complete blood count of the untreated patients. We further assessed the role of pretreatment NLR and PLR on overall survival (OS) and progression-free survival (PFS). RESULTS:Multiple myelomapatients with high NLR (≥2) experienced shorter OS (P=.02) and PFS (P=.01) compared with patients with low NLR (<2). Furthermore, among the patients with conventional chemotherapy, elderly patients, or patients with advanced stages, high NLR (≥2) was found to have a negative prognostic impact on OS and PFS. In the multivariate Cox analysis, we confirmed that the NLR was an independent prognostic factor for both OS and PFS (P=.000). But the differences in OS or PFS by PLR were not found in MMpatients. CONCLUSIONS: Our study suggests that NLR not PLR can be acted as an independent prognostic factor for analyzing the clinical outcome of MMpatients.
Authors: Yoji Kishi; Scott Kopetz; Yun Shin Chun; Martin Palavecino; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: Ann Surg Oncol Date: 2009-01-08 Impact factor: 5.344
Authors: Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir Journal: J Natl Cancer Inst Date: 2014-05-29 Impact factor: 13.506